Open Calls for Proposals

Young Investigator Awards aim to attract early career faculty with original ideas into the field of melanoma, thereby recruiting and supporting the next generation of melanoma research leaders. Awardees will be provided with funding to accomplish innovative and original, preclinical, translational, and/or early clinical research projects. Young Investigators are scientists within the first five years of their first academic faculty appointment. A mentorship commitment from a senior investigator at the applicant’s institution is required. Term: 3 Years Amount: Up to $85,000 per year for three years (up to $255,000 total)

https://www.curemelanoma.org/research/request-for-proposals/mra-general-rfp

Instruct-ERIC has opened its Fifth International Access Call, offering funding for researchers to access state-of-the-art structural biology technologies at Instruct Centres worldwide

Key details:

• Eligibility: As Israel is a member of Instruct-ERIC, all Israeli researchers are eligible to apply.
• Funding: Up to €5,000 per project to cover travel, accommodation, and access costs (including sample shipment for remote visits). Subsistence costs are not covered.
• Deadline:8 October 2026, 19:00 CEST.
• Application portal: Proposals must be submitted via the Instruct-ERIC submission system (login required).

This call is an excellent opportunity for researchers to strengthen international collaborations and gain access to advanced structural biology services.

For full submission guidelines please visit the Instruct-ERIC call page.

Should you have questions about eligibility or the application process, you may contact Instruct-ERIC support at support@instruct-eric.org.

We encourage interested researchers to apply and to share this opportunity within their networks.

For questions or help with submission, please contact rachel.elmoalem@weizmann.ac.il – at the IRCF team

Pilot Awards support senior investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-ofconcept, which may then leverage additional funding through more traditional avenues.  Term: 2 Years Amount: Up to $50,000 per year for two years (up to $100,000 total)

https://www.curemelanoma.org/research/request-for-proposals/mra-general-rfp

Drug Development RFP

The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. This funding opportunity concentrates on diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia.

Funding: Up to $5,000,000 based on stage and scope of research. No overhead.
Neuroimaging and CSF Biomarker RFP

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

• Developing novel PET ligands for clinical trials
• Supporting novel CSF biomarkers
• Validating innovative MRI approaches in larger cohorts
• Developing novel measures of functional activity such as EEG

Funding: Up to $600,000 based on stage and scope of research. No overhead.

Prevention RFP
to support precision prevention studies, combination therapy studies, and comparative effectiveness research that probe whether the use or choice of interventions may reduce the risk of Alzheimer’s disease or other dementias. Studies that are not in humans will not be considered.
Funding: up to $5,000,000 for clinical trials based on stage and scope of research. No overhead.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities

Academy of Kidney Cancer Investigators – Early-Career Scholar Award: Supports impactful kidney cancer research; and integrates new Early-Career Scholars (ECS) into a virtual academy providing intensive mentoring, national networking, research collaborations, and a peer group for early-career kidney cancer investigators

Funding: up to $1.2M for 4 years

Idea Development Award: Supports the development of innovative, high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes.

Funding: up to $1.2M for 3 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/kcrp

Clinical Trial Award: Supports rapid implementation of clinical trials with the potential to significantly impact ovarian cancer.  • Proposed projects may range from small, proof-of concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1 or 1/2).

Funding: up to $2.8M for 4 years

Ovarian Cancer Academy – Early-Career Investigator Award: Supports the addition of new early career investigators to the unique, interactive, virtual academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.

Funding: up to $1.125M for 4 years

Ovarian Cancer Clinical Trial Academy – Early Career Investigator Award:  Supports the addition of new ECIs to the unique, interactive, virtual Clinical Trial Academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.

Funding: up to $1.4M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=711101

The Program is designed to support early-stage, high-impact pilot projects that generate preliminary data, validate novel concepts, or de-risk innovative approaches with strong potential for future translational, clinical, or commercialization impact. Proposed projects should align with the mission of the ACT Rare Diseases Consortium and complement or expand the Consortium’s ongoing Clinical Projects. Clinical Project 1 aims to study the longitudinal natural history of syndromic CS. Clinical Project 2 aims to study surgical treatment outcomes of syndromic CS after cranial vault remodeling. Clinical Project 3 aims to study surgical treatment outcomes of syndromic CS after midface advancement.

Responsive topics include, but are not limited to:

* Disease mechanisms, pathophysiology, or target identification

* Biomarker discovery or validation

* Therapeutic development (e.g., small molecules, biologics, cell or gene therapies, and medical devices)

* Diagnostic or prognostic tools

* Data science, artificial intelligence/machine learning, and digital health approaches

Letters of Intent/Inquiry should be limited to one page.

Funding: $40,000 for one year.

https://grants.rarediseasesnetwork.org/grants/ACT-Cycle2-LOI

https://act.rarediseasesnetwork.org/pilot-study-program

Focused Pilot Award: Supports the exploration and development of impactful and innovative concepts under a patient centered focus area that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life.

Funding: up to $300K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=707102

Concept Award (CA): Supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers.

Funding: up to $140K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/rcrp

This award supports new and pioneering research ideas and pilot studies of high scientific risk to stimulate and develop the early detection field.

Eligibility: The PI has to be a scientist, clinician or healthcare worker based in a UK university, medical school, hospital or research institution. Supporting roles from international and commercial organisations may also be included as co-investigators and collaborators.

Funding: Up to £100k for one year.

www.cancerresearchuk.org/for-researchers/apply-for-and-manage-your-funding/our-funding-schemes/early-detection-diagnosis-primer-award

The nominee should have demonstrated academic excellence and achievements in the field of translational cancer research, which we define as a fundamental research discovery that has the potential for future clinical development for the benefit of cancer patients. Nominees may be working on research which has achieved proven clinical applications, or which has not yet done so but shows significant promise in this area.

Nominees must also meet the following criteria:

• Have no more than 15 years post-doctoral experience (or equivalent degree)
• Have spent at least the last five years working in Europe
• Presently be employed in a European institution

Self-nominations and nominations for EACR Board members cannot be accepted.

https://eacr.org/pezcoller-foundation-awards/translational-cancer-researcher-award

The purpose of this Request for Information (RFI) is to solicit ideas on NIH-wide challenges and opportunities from the public that may be of interest to the NIH Common Fund.

Background:  The Common Fund supports bold scientific programs that catalyze discovery across all biomedical and behavioral research. These programs bring together investigators and multiple NIH Institutes, Centers and Offices (ICOs) to collaborate on innovative research. Common Fund programs are expected to address high priority challenges for NIH as a whole and make a broader impact on the scientific community. Many Common Fund programs are designed to produce specific deliverables, such as broadly useful datasets, tools, technologies, research methods, or fundamental scientific paradigms. These deliverables are expected to have exceptional impact on the way science is conducted, our understanding of human physiology or disease, or our ability to support human health.

All Common Fund investments share the following criteria:

• Transformative – strong potential for exceptionally high and broadly applicable impact in biomedical/behavioral research
• Catalytic – time-limited investments of 10 years or less, designed to capitalize on new scientific knowledge or breakthroughs to accelerate and enable subsequent research
• Goal-driven – include defined goals to develop specific deliverables (such as new knowledge, data sets, resources, methods, or technologies)
• Synergistic – advance the missions of multiple NIH Institutes, Centers, and Offices (ICOs), leverage expertise from multiple ICOs, and accelerate research relevant to multiple diseases and conditions
• Novel – pursue innovative solutions to specific scientific challenges important to the NIH mission but that no other entity is likely or able to address

Information requested:  The NIH requests ideas for biomedical and behavioral research challenges and opportunities that may be of interest to the Common Fund. These ideas may inform activities to advance areas of science relevant to these challenges/opportunities, including, but not limited to, scientific workshops, pilot initiatives, and/or future Common Fund programs.

NIH encourages idea submissions that may include, but are not limited to, the following:

• A critical challenge or exciting emerging opportunity in biomedical/behavioral research
• Resources, tools, or knowledge that are needed to address the important challenge or opportunity
• Scientific advancements or other factors that make addressing the important challenge or opportunity particularly timely
• Critical challenges that small labs or research groups face with respect to funding, contracting, or navigating the regulatory landscape
• Priorities from “Advancing NIH’s Mission Through a Unified Strategy” and “Make Our Children Healthy Again Strategy.”

How to submit a response:  All responses must be submitted electronically by 11:59:59 pm (ET), September 19, 2026 using the following website https://rfi.grants.nih.gov/?s=6a22cf1d0957e14467009772.

Responses to this RFI are voluntary and may be submitted anonymously…  This RFI is for information and planning purposes only and is not a solicitation for applications …

https://grants.nih.gov/grants/guide/notice-files/NOT-RM-26-004.html

Through two prestigious Awards of €200,000 each, Fondation ARC rewards top-class researchers whose careers and work have let to major breakthroughs in cancerology.

www.fondation-arc.org/appels-a-projets/55th-fondation-arc-leopold-griffuel-awards

Melanoma Academy Scholar Award: Supports the addition of Scholars to a virtual academy providing intensive mentoring, national networking, collaborations and a peer group for earlycareer melanoma investigators.

Funding: up to $770K for 3 years

Survivorship Research Award: Supports studies addressing melanomaspecific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners

Funding: up to $1.02M for 3 years

https://cdmrp.health.mil/funding/erp

https://cdmrp.health.mil/funding/default

A joint effort to encourage and support a postdoctoral or clinical research fellow conducting primary cancer prevention research. The fellowship is intended to advance research that helps stop cancer before it starts by identifying, reducing, or interrupting cancer risk factors and the earliest biological processes that lead to cancer, while establishing a successful career path in this field.

Funding: This fellowship provides a two-year grant of $130,000 to support the salary and benefits of the fellow while working on a mentored primary cancer prevention research project. Up to 50% of the funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.

www.aacr.org/grants/aacr-world-cancer-research-fund-international-prevent-cancer-foundation-cancer-prevention-research-fellowship/

This program offers up to $100,000 for a one-year period and is intended for established scientists who maintain peer reviewed competitively funded scientific programs.

The Brain & Behavior Research Foundation funds the most innovative ideas in neuroscience and psychiatry to better understand the causes and develop new ways to effectively treat brain and behavior disorders. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, schizophrenia, as well as research in suicide prevention. BBRF’s Distinguished Investigator Grant program is designed to stimulate the development of key personnel and resources, to facilitate the rapid initiation of research in innovative areas, and to enable investigators to create unique scientific opportunities.

APPLY NOW

This scheme aims to de-risk early projects to facilitate further drug discovery research, funding, or partnering. We are seeking projects with strong therapeutic potential to deliver patient benefit.  We invite applications for early drug discovery proposals from across all cancer indications and modalities. Some examples of projects we might fund include the following areas:

* deconvolution and validation of novel targets and pathways

* novel therapeutic approaches to validated targets

* development of platforms, assays and screens to identify novel cancer therapeutics or targets

* drug discovery feasibility and progressing more advanced assets

Funding: Up to £250k for up to 18 months.

www.cancerresearchuk.org/funding-for-researchers/our-funding-schemes/therapeutic-catalyst

This scheme provides long-term support for established researchers to pursue an ambitious and creative programme of work addressing key questions in the cancer field. Proposals should be centred on a core overarching vision, explored via a set of connected aims. We encourage collaborative teams and multidisciplinary approaches.

Eligibility: The PI has to be a scientist, clinician or healthcare worker based in a UK university, medical school, hospital or research institution. Supporting roles from international and commercial organisations may also be included as co-investigators and collaborators.

Funding: Up to £2.5m over 5 years.

www.cancerresearchuk.org/for-researchers/apply-for-and-manage-your-funding/our-funding-schemes/discovery-programme-award

Funds activities that hold promise of identifying therapies (cures) for paralysis in humans. It has particular focus on placing projects in the research pipeline, that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. The development of effective therapies for chronic injury is a high priority for the organization.  Basic research will be supported if it has clear potential to accelerate progress at the applied end of the continuum and/or if it reflects innovative research or a ‘change of direction’.

Funding: $5K to $75K for 1 year (second year considered, no overhead)

https://mcpf.org/new-investigator-grant-application/

https://mcpf.org/wp-content/uploads/2025/02/MCPF-Research-Guidelines-1.doc

Funds an established, leading PIs pursue a potentially ground-breaking, high-risk project in basic research in ALS.
Funding: 200K CHF (~880,000 NIS) for 2 years (one or two grants will be funded).
https://www.radala-foundation.com/index.html

The Innovator Awards Program enables researchers worldwide to test ideas and collaborate to advance the understanding of IBD. The Foundation encourages applications for high-impact basic and translational research projects that use artificial intelligence (AI), machine learning (ML), big data analytics and various model systems to deepen our understanding of the mechanisms in IBD and accelerate therapeutic discovery in the field.

Funding: Iindividual research projects – up to $150,000;  Collaborative projects involving multiple investigators – up to $300,000. The award period is 12 months.

https://krfoundation.org/grants/funding-opportunities/innovator-awards/

PROGRAM MISSION STATEMENT: The program will support highly innovative translational research that provides a step-change improvement in therapy for DMG, including diffuse intrinsic pontine glioma (DIPG), hereinafter referred to collectively as DMG. DMG primarily affects children between 5 to 10 years old but can affect younger children, adolescents, and young adults (CAYA). The program seeks translation into the clinic within 18-24 months. By fostering rigorous, translational, and accessible research, the program aims to accelerate treatments with high potential for significant increases in long-term survival and high quality of life for CAYA diagnosed with DMG. The program will also consider early-phase clinical trials representing highly innovative, out-of-the-box approaches to DMG treatment.

RESEARCH PROJECT CRITERIA:

This funding call invites proposals that primarily aim to design, validate, and test ground-breaking interventions to treat DMG resulting in a step-change of long-term survival and high quality of life for CAYA patients. Projects may include:

* Pioneering therapeutic approaches as proof of concept

* Novel combination treatment strategies

Proposals should be focused on research at the preclinical research stage or later, i.e. candidate targets and/or interventions should already have been identified. The project must aim to deliver interventions to patients in a clinical research study within 18-24 months of the project start. For studies focused on earlier stages of clinical development, where later-stage trials and/or implementation of a final intervention is outside the scope of the study timeframe and budget, a clear line of sight to the following steps required for intended implementation should be articulated. All proposals should align with SU2C and PNOC’s mission.

Funding: Teams may apply for total support up to $1,000,000 for up to a 2-year term. Funding is available for up to two Challenge Grants. Towards the end of the grant term, selected team(s) that successfully demonstrate high potential for treatment with long-term survival and high quality of life for CAYA patients with DMG may be eligible for larger-scale funding to support an early phase clinical trial or an expansion of an early phase trial.

Research may be carried out internationally. There are no citizenship or residency status restrictions for team members.

https://standuptocancer.org/science/grant-opportunities/

Stand_Up_To_Cancer_Sept_30_2026

Provide more experienced researchers with seed funding to enable them to collect the preliminary data needed to obtain major, long-term funding from other organizations.

Funding: $100K for one year (No overhead, with possible 1 more year renewal)

https://hdfoundation.org/apply

Resource Development Award: Supports the development of a multiomic atlas generated from well-annotated human BMF samples, with omic data derived from marrow specimens

Funding: up to $1.25M for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/bmfrp

Next Generation Research Grant in ALS: This grant targets early career researchers who are studying disease mechanisms, diagnosis, or treatment of ALS and whose research has potential relevance beyond ALS to other diseases.

Funding: $150,000 for 2 years.

https://www.americanbrainfoundation.org/wp-content/uploads/2026/07/ABF-Next-Gen-RFP_ALS-2yr_2027_rev20260615.pdf

https://proposalcentral.com/GrantOpportunities.asp?GMID=359

Richard Olney Clinician Scientist Grant in ALS: This three-year award supports clinical or preclinical research in ALS. This grant targets early career researchers who are studying disease mechanisms, diagnosis, or treatment of ALS and whose research has potential relevance beyond ALS to other diseases.  This grant is funded by The ALS Association and American Brain Foundation and administered by the American Brain Foundation.

Funding: $240,000 for 3 years

https://www.americanbrainfoundation.org/wp-content/uploads/2026/07/ABF-Next-Gen-RFP_ALS-Olney_2027_rev20260615.pdf

https://proposalcentral.com/GrantOpportunities.asp?GMID=359

supports clinical or preclinical research in peripheral neuropathy. This grant targets early career researchers who are studying disease mechanisms, diagnosis, or treatment of peripheral neuropathy and whose research has potential relevance beyond peripheral neuropathy to other diseases.

This grant provides $75,000 per year for two years, for a total of $150,000.

https://www.americanbrainfoundation.org/wp-content/uploads/2026/07/ABF-Next-Gen-RFP_Peripheral-Neuropathy_2027_rev20260623.pdf

https://proposalcentral.com/GrantOpportunities.asp?GMID=359

This two-year award supports clinical and translational research and training in neuromuscular disease. This grant targets early career researchers who are studying disease mechanisms, diagnosis, or treatment of neuromuscular disease and whose research has potential relevance beyond neuromuscular disease to other conditions. The purpose of this grant is to promote neuromuscular clinical and translational research through fellowships to trainees and to promote the activities of the Neuromuscular Study Group.

This grant provides $75,000 per year for two years, for a total of $150,000

https://www.americanbrainfoundation.org/wp-content/uploads/2026/07/ABF-Next-Gen-RFP_Neuromuscular_NMSG_2027_rev20260702.pdf

https://proposalcentral.com/GrantOpportunities.asp?GMID=359

CDA Award provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed. Applications in all areas of cancer research are accepted from U.S. and international applicants.

For 2027, dedicated donor funding is available for specific areas, including but not limited to those listed below. This list will be updated as new funding is confirmed.

• CDA in Palliative and Supportive Care in Oncology
• Breast cancers

Eligibility:

Applicants must meet the following criteria:

• A physician (MD, DO, or international equivalent with explanation) working in any country.
• In the first to fourth year of a full-time primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission. Faculty appointments may begin with the entry-level faculty position within the applicant’s institution (i.e., Instructor/Lecturer, Assistant Professor, Assistant Member).
• Have a valid, active medical license in the country where the research will be conducted during the CDA award term.
• Have completed productive postdoctoral research and demonstrated the ability to undertake independent investigator-initiated clinical research.
• A current ASCO member or have submitted a membership application with the grant application. To apply for new membership, or to renew an existing membership, visit asco.org/membership.
• Able to commit at least 50% of their time to research (applies to total research activities overall, not just the proposed CDA project) during the award period.
• Have a mentor from the sponsoring institution. If the mentor is not an ASCO member, a supporting letter from an ASCO member from the sponsoring institution must be included.
• Be up-to-date and in compliance with all requirements (e.g., progress reports, final reports, budget summaries, IRB approvals, etc.) of any past grants received from Conquer Cancer.
• Applicants with concurrent federal career development awards (e.g., K23, K08, or any other type of career development award), career development awards from private foundations, and institutional training grants (T32, KL2/K12 or equivalent) are eligible to apply provided there are no scientific and budgetary overlaps. Note: Conquer Cancer must be informed when a CDA recipient receives other career development awards during the term of the CDA and reserves the right to determine that the CDA may not be held concurrent with other funding. Past recipients of training fellowships (e.g., Young Investigator Award or an F32 grant) are eligible to apply.
• Applicants should not have been a Principal Investigator on any large project grants (e.g., R01 or international equivalent).

Applicants who are uncertain about their eligibility are encouraged to refer to the Eligibility section in the FAQ or contact our grants team for clarification and provide their latest CV for evaluation.

NOTE: While first year faculty may be eligible for both the Young Investigator Award (YIA)  and the Career Development Award (CDA) programs, they are restricted to a single submission. Applicants must only submit one application to either the YIA or the CDA competition and may not submit to both programs simultaneously.

Funding: up to $200,000 over three years.

www.asco.org/career-development/grants-awards/funding-opportunities/career-development-award

CCF aims to find a cure and advance scientific and medical research related to the diagnosis, treatment, and cure of cholangiocarcinoma (bile duct cancer) to improve the quality of life of those affected by cholangiocarcinoma.

The Research Fellowship Program supports early-career, high- quality, innovative researchers worldwide focusing on studying cholangiocarcinoma. The intent is to help them better understand this complex disease and accelerate the pace of finding a cure. Prior experience in the field of cholangiocarcinoma is not required.

Funding: up to $75,000 for one year.

www.cholangiocarcinoma.org/funding-opportunities-with-ccf

https://www.cholangiocarcinoma.org/wp-content/uploads/2026/08/Call-for-LOI-2027-CCF-Fellowship-1-1.pdf

This programme funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson’s. We do not fund research which is directed at symptomatic relief.

For preclinical research, we fund grants up to £250,000 (GBP) and prioritise projects that are likely to lead to clinical trials in people with Parkinson’s within 5 years. For clinical research, we fund clinical trials and sub-studies of trials in people with Parkinson’s. The grant amount is flexible, so please contact us ahead of submission if you are thinking of applying for a clinical trial.

The ‘Research Strategy’ provides more information on the types of research we fund, our funding priorities and how we provide funding.

www.cureparkinsons.org.uk/research/for-researchers/apply-for-funding/quarterly-research-grant

Research Strategy: www.cureparkinsons.org.uk/2025/11/an-update-to-our-research-strategy

The IASLC’s Career Advancement Grant aims to support and facilitate the career advancement of mid-career professionals within the thoracic oncology field by bridging the gap between early-career funding opportunities and more advanced support mechanisms. This grant aims to provide the necessary resources and motivate these professionals to continue their research endeavors amidst their demanding schedules. Additionally, this grant will facilitate the generation of preliminary data to secure additional larger funding in the future allowing investigators to continue contributing to the field of lung and thoracic malignancies.

Funding Priority:

This grant aims to fund research projects led by mid-career professionals that focus on prevention, diagnosis, treatment, and all other aspects of lung cancer and thoracic malignancies. Research proposals with a focus on multidisciplinary and global research projects are encouraged to apply. Applicants of underrepresented specialties and low-and middle-income economies are highly encouraged to apply.

Eligibility Criteria:

IASLC Career Advancement Grant is open to candidates worldwide. At the time of application, the applicant must meet all these requirements to apply for the Career Advancement grant:

1. The applicant (MD, DO, PhD, PharmD, or equivalent) must be a mid-career professional within 6-15 years from initial faculty appointment.
2. As of the start of the grant term (July 1, 2026), the applicant must not have been awarded a single, independent, major award (i.e. R01, DOD, private foundation, or international equivalent) valued at $250,000 or more annually. This limitation applies to each award individually and does not apply to the combined funding an applicant may have been awarded from multiple sources. Prior mentored, early-career focused, career-development grants are allowed.
3. Applicants may not concurrently hold ongoing multi-year mentored awards (i.e. YIA, CDA, etc.). If an applicant has previously received a mentored grant, it must be completed before the start of the IASLC Career Advancement Grant term on July 1, 2026.
4. The applicant must be a member of the IASLC, and if selected for grant funding, must maintain IASLC membership for the duration of the grant.

Funding: $100,000 for one year.

https://iaslc.secure-platform.com/researchgrants/page/Grant_Guidelines/IASLC_CAG

IASLC Career Advancement Grant RFP

TRP is designed to accelerate the progression of promising scientific discoveries toward clinical application in blood cancers. The TRP supports projects with a clear path to clinical impact. Early-stage or discovery-focused research may be better suited for our Discovery Grant Program (DGP), and applicants with such projects are encouraged to apply through that mechanism.

For the 2027 grant cycle, TRP applications must demonstrate translational readiness. The following criteria apply:

• Small molecule therapies: Applications must include in vivo proof of concept (POC) in appropriate animal models. In select cases, strong in vitro POC using patient-derived samples may be considered, depending on the mechanism of action.
• Cellular and immunotherapies: In vivo POC is strongly encouraged. However, in vitro POC may be acceptable where it is most appropriate for the therapeutic approach.

Funding:  $750,000 over three years.

https://bloodcancerunited.org/research/grants/translational-research-program-trp

https://llsorg.widen.net/s/zgns9bkdj6/en-trp-guidelines-and-instructions-final

This award recognizes an individual who has made significant research contributions in the search for the cause, prevention of, and cure for ALS. The criteria being used to determine the recipient include recent major scientific impact, long-term scientific impact, and overall impact to ALS.

Funding: $50,000 prize to be used by recipient to continue ALS research.

www.aan.com/research/sheila-essey-award-for-als-research

www.als.org/research/researchers/research-funding-opportunities

Early Investigator Research Award: Supports Parkinson’s disease (PD) research opportunities for investigators in the early stages of their careers; however, the investigator need not have previous Parkinson’s disease research experience.

Funding: up to $1M for 2 years

Investigator-Initiated Research Award: Supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to PD research.  • Supports the full spectrum of research from basic pre-clinical science through clinical trials.

Funding: up to $2M for 3 years

https://cdmrp.health.mil/funding/prp

https://ebrap.org/eBRAP/public/Program.htm

The Initiative purpose is to accelerate the translation of research discoveries into clinical trials. Through the CAI, the Lustgarten Foundation will provide academic, clinical researchers the opportunity to propose science-driven concepts seeking to advance the development of new therapies for pancreatic cancer patients while furthering our understanding of disease biology.

Provides academic, clinical researchers the opportunity to propose science-driven concepts seeking to advance the development of new therapies for pancreatic cancer patients while furthering our understanding of disease biology.  The CAI is meant to support trials concepts that are:

• Innovative and highly collaborative
• Based on strong pre-clinical and/or clinical scientific rationale
• Utilizing deep, translational analyses to demonstrate on-target drug mechanism(s) of action and hypotheses around disease biology
• Advancing the development of novel therapies for pancreatic cancer patients with plans for continuation, if successful

Qualifications and Requirements of Research Investigator(s)

Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent degree and have a faculty position or equivalent at a college, university, medical institution, or other research facility. Proposals may be submitted by domestic and foreign non-profit or public organizations, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government. There are no citizenship requirements for this program.

Research Investigator(s) funded through the CAI typically:

• Are leading significant pancreatic cancer and/or relevant focus area research
• Have a demonstrated track record of significant contributions to the field as evidenced by publications, peer-reviewed funding and an ability to advance projects to clinical impact
• Are willing to interact and/or collaborate with researchers at outside institutions including the Lustgarten Translational Advisory Group and other Lustgarten Foundation-Funded Investigators

Funding: While the budget and duration of funding will be dependent on the needs of each trial, CAI trials are typically funded up to a total budget of $1.5M – $2M over a period of up to 3 years.

Provides funding for seed or pilot research projects. The emphasis lies in evaluating feasibility and refining methodologies, shaping the trajectory of potential larger-scale studies.

Funding: Up to $25K for single institution & up to $50K for multi-institution projects.   The funding period is one year (with an opportunity for an additional competitive one year renewal).

https://tango2research.org/research/grants

Designed to support early-stage, pre-development concepts — innovations that have not yet been built or tested, but that hold the potential to transform the landscape of cancer immunotherapy.
The most competitive applicants will propose innovations that address areas where technological advancement can have the greatest impact on cancer immunotherapy and patient outcomes. Such technologies may include, but are not limited to:
Computational systems biology approaches, Advanced cancer (or molecular) profiling technologies, Real-time visualization technologies, Complex multicellular culture systems and Novel therapeutic technologies.
Funding: seed funding of up to $600K over 2-4 years (10% overhead in addition to awarded funds)
https://www.cancerresearch.org/technology-impact-award

Provides support to promising young researchers to advance the understanding of complications and therapeutic strategies in the context of hematological diseases.

Applicants must have received a doctoral degree (PhD, MD, or equivalent achievements) in a field pertinent to the grant within the last 10 years from the grant call start date.

Applicants from all countries are welcome to apply.

Funding:  € 240,000 for a time period of three years.

https://professional.dkms.org/research-publications/research-grant

NAF funds research through 7 distinct award mechanisms:

-Early Career Investigator Award: a $50,000. 1-year, merit-based, nonrenewable grant designed to support outstanding early-stage scientists who have completed their postdoctoral training within the past 6 years and hold a junior faculty or clinical fellow appointment. This award aims to foster the development of independent research careers by providing seed funding for innovative, high-impact studies in the field of ataxia. Proposals are welcome across the full spectrum of basic, translational, and clinical research, but must have a clear and significant focus on advancing our understanding of the causes, pathogenesis, or treatment of hereditary, sporadic, or acquired ataxias.
-Research Seed Money Award: provides support for new and innovative studies that advance understanding of the cause, pathogenesis, or treatment of hereditary, sporadic, and acquired ataxias. These $50,000, 1-year, merit-based, nonrenewable grants serve as seed funding to assist investigators during the early or pilot phases of research, or as supplemental funding for ongoing innovative projects demonstrating a critical need. It is expected that funded projects will generate preliminary data to support applications for larger grants from other funding sources.
-Pioneer SCA3 Translational Award: s annually granted to independent researchers to support outstanding research proposals that aim to make significant advancements in the development of treatments and/or improvements to patient care for Spinocerebellar Ataxia Type 3 (SCA3). This 1-year, merit-based, nonrenewable grant provides $100,000 in direct research funding. Proposals must have a predominant focus on SCA3 preclinical, translational, or clinical research.
-Michael Lundquist Grant to Advance MSA-C Research:  a $50,000, 1-year, merit-based, nonrenewable grant awarded annually to independent researchers for outstanding proposals that aim to make meaningful advancements in the treatment and care of individuals affected by multiple system atrophy, cerebellar subtype (MSA-C). While proposals may include aspects relevant to other forms of ataxia, the primary focus must be on preclinical, translational, or clinical research directly related to MSA-C.

Researcher Resources

Funding to establish the UK Obesity Research Institute, a major multidisciplinary research initiative focused on understanding the biological mechanisms underlying obesity and developing new approaches for the prevention and treatment of obesity and its complications. This is a large-scale, institute-building opportunity, rather than a standard individual research grant. Researchers interested in participating should ideally establish contact with a relevant UK-based research group/consortium early in the process.

The application must be led by a UK research organisation eligible for MRC funding.

International researchers/institutions may potentially participate as collaborators, subject to UKRI/MRC eligibility and funding rules.

Funding available is up to £72 million for an initial seven years, with the potential to renew.

https://www.ukri.org/opportunity/uk-obesity-research-institute/

Supports Bavarian state and church-affiliated universities as well as universities of applied sciences (UAS) in establishing international research collaborations and preparing joint research funding proposals.

The funding enables researchers to build new international partnerships and prepare joint third-party funding proposals. Funding is exclusively provided for meetings between Bavarian researchers and their specific partner institutions that serve the targeted initiation or deepening of joint cooperation. The programme therefore focuses on institutionally anchored research partnerships.

Funding: up to EUR 10,000 per project

https://www.bayfor.org/en/about-us/mission/initial-funding-programme-bayintan.html

Research projects focused on human gut microbiota related to health and disease. Either clinical or fundamental research proposals can be submitted.

The project should involve Microbiome analysis, Immunophenotyping and a dietary component.  The project should be primarily performed in humans and in a disease context (Studies purely on healthy subjects are excluded).  Pure observational studies should be avoided and some experimental validation is expected.

Funding: up to €200,000 over 3 years.

www.biocodexmicrobiotafoundation.com/international-research-grant/international-call-projects

Process Development Grant:  provides up to $100K to support innovative processes, technologies, tools, and operational models that advance the safe, available, and effective delivery of transfusion medicine and biotherapies. The grant is intended to help improve operational performance, efficiency, quality, safety, accessibility, or decision support.

https://www.aabb.org/foundation/process-development-grant

Early-Career Scientific Research Grant:  provides up to $100K to support investigator-initiated, original research in blood banking, transfusion medicine, and biotherapies. The grant is intended to help early-career investigators advance toward research independence through one- or two-year projects.

An early-career investigators is one that has completed a terminal research degree or medical residency – whichever date is later – within the past 10 years of the grant application deadline and has not yet been awarded a substantial research grant (i.e. NIH R01).

https://www.aabb.org/foundation/early-career-scientific-research-grants-program

This award funds exceptional science to drive transformational change in how and when early cancers and pre-cancerous states are detected and diagnosed.

Eligibility:  The PI has to be a scientist, clinician or healthcare worker based in a UK university, medical school, hospital or research institution. Supporting roles from international and commercial organisations may also be included as co-investigators and collaborators.

Funding: Up to £500k over 4 years.

www.cancerresearchuk.org/for-researchers/apply-for-and-manage-your-funding/our-funding-schemes/early-detection-diagnosis-project-award

We support innovative basic, translational, and clinical research that advances understanding and care for LGS.
Priority Research Areas: LGS biomarkers that predict disease course and/or treatment response / Mortality in LGS / Medical device use in LGS / Disease-modifying therapies targeted to the LGS Secondary Brain Network / Natural history of LGS / Non-seizure issues & quality of life in LGS / Prevention, reversal, and/or stabilization of LGS / Neurodegeneration in LGS / Pediatric-to-adult transition of care in LGS
Funding: up to $75K over 1–2 years.
www.lgsfoundation.org/365-research-grant
www.lgsfoundation.org/wp-content/uploads/2025/11/RFP_-LOI-and-Full-Proposal-Instructions-.docx.pdf

Specific Defect Research Program
Funding collaborative research that explores individual immune system defects and their clinical impact.
Funding: up to $50K over two years.
C.H.I.L.D.R.E.N Global Research Program
Supports research focused on improving outcomes for children with PI worldwide—advancing diagnostics, treatment, and healthcare equity, especially in developing countries.
Funding: up to $50K over two years.
G.E.N.I.E. Program
Advance physician education, foster global collaboration, and promote early diagnosis and better care for Primary Immunodeficiency patients worldwide.
Funding: up to $10K for one year
www.info4pi.org/medical/grants

To provide seed funding for highly innovative research with significant potential to accelerate the mission of the Lustgarten Foundation (Early Detection and Interception, Therapeutic Development, Personalized Medicine).
Preference will be given to proposals addressing understudied and/or poorly understood aspects of pancreatic cancer biology.
Proposals that involve collaborations across groups or that bring new expertise and/or technology into the field will be preferred.
Funding: up to $110K for 1 year
https://lustgarten.org/innovation-collaboration-rfa/

Supports studies that employ CureGN and or NEPTUNE resources to advance clinical and translational research in glomerular disease.  Projects can include, but are not limited to, those that can be used to generate feasibility data to support advancement of promising future studies and projects to develop clinical assays, or protocols, or early phase clinical trials.

Funding: up to $250,000 per project in direct costs only, paid over a 2-year period

https://nephcure.org/about/our-impact/grant-opportunities/

To advance transformational collaborative projects to provide new insights into disease mechanisms or create or implement tools and technologies not previously applied to Huntington’s disease research for the advancement of therapeutics. General areas include but are not limited to: whether modulation of somatic repeat instability is disease modifying, whether and how cellular, biochemical or molecular insights in HD systems are predictive of disease, or how to apply unexplored therapeutics for clinical application (inclusive of biomarkers). Projects that discover disease modifying targets and incorporate novel tools or technologies are encouraged. Projects must justify how results could ultimately connect to therapies.

Funding: $300K-$500K per year for up to a two-year period.

https://hdfoundation.org/apply

Research proposals involving the microbiota and its implication in Women’s Health and Disease.  Either clinical or fundamental research proposals can be submitted.

Proposals could include, but are not limited to, mechanistic studies elucidating how the penile microbiome contributes to the establishment, persistence, and recurrence of vaginal dysbiosis, including bacterial vaginosis. Areas of interest include microbial transmission dynamics during sexual activity, niche adaptation and persistence of BV-associated taxa in the penile environment, and the functional consequences of these interactions for vaginal community stability.  Studies evaluating how current and emerging interventions, such as antibiotics, topical or systemic partner therapies, circumcision, or live biotherapeutic products, alter penile microbial ecology and, in turn, influence treatment response and recurrence risk in female partners are also encouraged.

STI-related projects, except bacterial vaginosis, are not eligible.  Clinical studies may be submitted only after approval by an accredited ethics committee.

Funding: up to €200,000 over 3 years.

www.biocodexmicrobiotafoundation.com/women-health-award/microbiota-womens-health-international-call-projects

This award funds long-term, integrated and potentially renewable programmes of exceptional science to drive forward a transformational change in how early cancers and pre-cancerous states are detected.

Eligibility:  The PI has to be a scientist, clinician or healthcare worker based in a UK university, medical school, hospital or research institution. Supporting roles from international and commercial organisations may also be included as co-investigators and collaborators.

Funding: Up to £2.5m over 5 years.

www.cancerresearchuk.org/for-researchers/apply-for-and-manage-your-funding/our-funding-schemes/early-detection-diagnosis-programme-award

 (Abstracts may be submitted at any time until the closing date)

AOI #20 DRIVe Forward

Aims to develop products, capabilities, and technologies to detect threats, improve patient care, including ancillary supplies and resources, as well as novel approaches to develop, clinically validate, and deploy/distribute MCMs rapidly and agnostically.

Especially interested in proposals that aim to address one or more of the following topics:

1. Microbiome-based therapies
2. Resilience to infection
3. Next-generation vaccines
4. Next-generation therapeutic antibodies
5. Artificial blood products
6. Extremely mobile viral diagnostic platforms for use in extremely remote settings
7. Non-pharmacological approaches for enhanced immunity

Funding: up to $750K.

https://drive.hhs.gov/partner.html

https://drive.hhs.gov/files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_01.pdf

Frontier Grants facilitate transitions from basic research to attractive prospects for biotech investors

Lundbeck Foundation has now introduced Frontier Grants to support critical activities to advance and consolidate basic research projects, with significant potential, into attractive prospects for investors. The purpose of the grant is to advance mature research projects to become financeable and commercially tangible venture opportunities.

Purpose:

A Frontier Grant (FG) provides financial and interactive support to test and develop the commercial and translational potential of a basic research finding together with the researcher and allowing for mentoring and professional development activity.

Criteria – Who can apply:

Field must be within biomedicine or health sciences, i.e., not limited to brain health.

The research must be affiliated with a Danish non-commercial research institution – international collaboration is allowed.

duration of up to 18 months and a max budget of DKK 5.0 M (with optional 2.5 M and +6 months extension).
https://lundbeckfonden.com/apply-grants/frontier-grants

(Pre-proposals/pre-applications may be submitted at any time throughout the 5-year period from the BAA release date to the BAA closing date)

Research Areas of Interest (please see BAA for more details)

1. Damage Control Resuscitation
2. Prolonged Field Care (PFC)
3. Portable Lab Assays and Diagnostics
4. Force Health Protection and Environmental Medicine
5. Brain Health
6. Immune Response
7. Chronic Pain
8. Automation of Systematic Reviews and Metanalysis
9. Medical Simulation and Training Technologies
10. Human Performance Optimization
11. Canine Medicine and Performance

Most projects are anticipated to have a total cost at or below $1,500,000 (including indirect costs). Projects that have a total cost higher than $1,500,000 (including Indirect costs) with outstanding scientific merit that meet a critical need may be accepted; however the total cost of these projects are not to exceed $5,000,000.00 (including Indirect costs).

Duration: up to 5 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=549113

to advance the current understanding of Malan syndrome and identify disease-modifying treatments.

Funding: up to $30,000 for one year, may be renewed for a second year, based on satisfactory progress.

www.malansyndrome.org/research-grant-program

https://drive.google.com/file/d/1m-RReH2f7jUsmYsXtknPSVORepn_ecdr/view